Outlook Therapeutics, Inc. Alternatives & Competitors

12 companies similar to Outlook Therapeutics, Inc. — ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO

Clearside Biomedical, Inc.

Revolutionizing the delivery of therapies to the back of the eye through the suprachoroida...

39 Post-IPO Equity $203.90M

Biotechnology Health Care +3

Eton Pharmaceuticals

Rare diseases call for a rare company.

39 Post-IPO Equity $38.10M

Deer Park, United States

Biopharma Biotechnology +2

Ocuphire Pharma

Restoring Vision and Clarity

15 Post-IPO Equity $24.56M

Farmington Hills, United...

Biopharma Biotechnology +1

Soligenix, Inc.

We are a late-stage biopharmaceutical company focused on developing & commercializing prod...

27 Post-IPO Equity $55.97M

Princeton, United States

Biopharma Biotechnology +1

Track all Outlook Therapeutics, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

ONL Therapeutics

Helping patients see the future

39 Venture round

Ann Arbor, United States

Biotechnology Health Care +2

Compare

Sopherion Therapeutics

Innovating metastatic breast cancer treatment through advanced nanotechnology solutions.

Series C $163.00M

Biotechnology Health Care +1

Othera Pharmaceuticals

27 Debt Financing $23.62M

Exton, United States

Biotechnology Health Care +1

X4 Pharmaceuticals

Enabling a better future for people with rare immune disorders

137 Post-IPO Debt $520.31M

Boston, United States

Biotechnology Health Care +2

Palatin Technologies

We discover and develop novel therapeutics for patients living with inflammatory and autoi...

50 Post-IPO Equity $133.90M

Biotechnology Health Care +1

InnoCare Pharma

Science drives innovation for the benefit of patients!

120 Post-IPO Equity $215.00M

Beijing, China

Biotechnology Health Care +1

Gamida Cell Ltd.

Working to turn cells into powerful therapeutics for patients with cancer.

93 Post-IPO Debt $292.51M

Boston, United States

Biotechnology Health Care +3

QRxPharma

Pioneering pain management with innovative products and advanced abuse prevention technolo...

Post-IPO Equity $34.50M

Biopharma Biotechnology +1

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing ONS-5010 \/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics...

Taxonomy

Biopharmaceutical Company, Ophthalmic Formulation, Retinal Diseases, Drug Development, Wet AMD, DME, BRVO, FDA Approval, Regulatory Pathway, Commercialization, Global Markets

Frequently Asked Questions

Companies similar to Outlook Therapeutics, Inc. include Clearside Biomedical, Inc., Eton Pharmaceuticals, Ocuphire Pharma, Soligenix, Inc., ONL Therapeutics. They work in Biotechnology and Pharmaceutical and share Outlook Therapeutics, Inc.'s focus on drug development, commercialization and fda approval.

Bounce Watch lists 12 companies that share Outlook Therapeutics, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Outlook Therapeutics, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Outlook Therapeutics, Inc. Profile Clearside Biomedical, Inc. Alternatives Eton Pharmaceuticals Alternatives Ocuphire Pharma Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Outlook Therapeutics, Inc. on 12 Sep 2024. The 12 companies listed here were last checked between 26 Jul 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.